Compare KNSA & OWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KNSA | OWL |
|---|---|---|
| Founded | 2015 | 2020 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 6.9B |
| IPO Year | 2018 | 2020 |
| Metric | KNSA | OWL |
|---|---|---|
| Price | $95.50 | $9.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 19 |
| Target Price | ★ $111.57 | $12.66 |
| AVG Volume (30 Days) | 869.4K | ★ 19.5M |
| Earning Date | 10-27-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 9.91% |
| EPS Growth | ★ 225.00 | N/A |
| EPS | ★ 1.14 | 0.07 |
| Revenue | ★ $677,564,000.00 | $567,754,000.00 |
| Revenue This Year | $54.80 | $0.65 |
| Revenue Next Year | $28.50 | $9.48 |
| P/E Ratio | ★ $83.44 | $132.57 |
| Revenue Growth | ★ 60.09 | 7.56 |
| 52 Week Low | $37.02 | $7.95 |
| 52 Week High | $99.31 | $17.00 |
| Indicator | KNSA | OWL |
|---|---|---|
| Relative Strength Index (RSI) | 58.64 | 41.27 |
| Support Level | $72.76 | $9.14 |
| Resistance Level | $98.90 | $9.50 |
| Average True Range (ATR) | 4.32 | 0.44 |
| MACD | -0.24 | -0.10 |
| Stochastic Oscillator | 68.28 | 8.88 |
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Blue Owl Capital is one of the world's largest alternative-asset managers, $307.4 billion in total managed assets, including $187.7 billion in fee-earning AUM, at the end of 2025. The company has three core business segments: global private equity, (with $69.1 billion in total AUM and $39.5 billion in fee-earning AUM), private credit ($157.7 billion/$99.5 billion), and real estate/real assets ($80.6 billion/$48.7 billion). The firm primarily serves institutional investors (68% of AUM) and high-net-worth individuals (32%). Blue Owl operates through more than 20 offices in the Americas, and the EMEA and Asia-Pacific regions.